Dr. Bobak Parang Announced as Recipient of Rising Tide/LUNGevity Research Award for Overcoming Drug Resistance

LUNGevity Foundation and Rising Tide Foundation for Clinical Cancer Research awarded $620,000 to an early-phase clinical trial at The Ohio State University Comprehensive Cancer Center. The trial will test whether combining FDA-approved alectinib with osimertinib can inhibit FER and eliminate drug-tolerant persister cells in EGFR-mutant NSCLC; efficacy has not yet been established.

Analysis

Investment significance is low near term: a $620,000 award funding an early-phase study does not establish clinical benefit or a material revenue opportunity for either drug. The investable signal is scientific, not commercial. If FER inhibition meaningfully suppresses drug-tolerant persister cells, combining alectinib with osimertinib could extend time on EGFR-targeted therapy and create a repurposing pathway; however, added toxicity, drug interactions, or failure to demonstrate target engagement could erase that benefit. Longer treatment duration would not automatically translate into better economics if combination tolerability limits use or requires dose changes.

Over the next 1–3 months, verify trial registration, protocol, enrollment status, endpoints, and whether patients receive the combination alongside standard therapy. Any valuation reaction to the announcement alone is likely unsupported. Over 6–18 months, safety and pharmacodynamic evidence would matter before efficacy claims; timing and data availability are not specified. The result could inform broader drug-resistance research, but this single study should not be generalized across EGFR-mutant cancers or treatment settings.

Contrarian view: the positive framing emphasizes an FDA-approved combination, but approval of each drug separately does not validate this combination or establish its safety and effectiveness in this population. No direct public-equity trade is supported by the supplied information.

Key Decisions for Investors

• No event-driven position based solely on the award announcement; the funding amount and early-stage status are not a credible near-term earnings catalyst.
• Add the study to a clinical-development watchlist. Reassess only after confirming registration, design, enrollment, and evidence of FER target engagement and combination tolerability.
• Treat any future efficacy signal as conditional: a thesis would weaken materially if safety limits dosing, the study fails to show pathway inhibition, or resistance-free treatment duration does not improve against an appropriate comparator.